1007-11-0

Basic information

• Product Name: 2,4-pyrimidinediamine, 6-chloro-N~4~,N~4~-dimethyl-
• Synonyms: 2,4-pyrimidinediamine, 6-chloro-N~4~,N~4~-dimethyl-;6-chloro-N~4~,N~4~-dimethylpyrimidine-2,4-diamine;6-chloro-N~4~,N~4~-dimethyl-2,4-pyrimidinediamine(SALTDATA: FREE);6-chloro-N~4~,N~4~-dimethyl-2,4-pyrimidinediamine;(2-amino-6-chloro-pyrimidin-4-yl)-dimethyl-amine;6-chloro-N',N'-dimethyl-pyrimidine-2,4-diamine;6-chloro-N',N'-dimethylpyrimidine-2,4-diamine
• CAS NO: 1007-11-0
• Molecular Formula: C₆H₉ClN₄
• Molecular Weight: 172.61546
• Mol File: 1007-11-0.mol

Chemical Properties

• Boiling Point: 384.4°Cat760mmHg
• Flash Point: 186.3°C
• Appearance: /
• Density: 1.347g/cm³
• Vapor Pressure: 4.1E-06mmHg at 25°C
• Refractive Index: 1.635
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2,4-pyrimidinediamine, 6-chloro-N~4~,N~4~-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-pyrimidinediamine, 6-chloro-N~4~,N~4~-dimethyl-(1007-11-0)
• EPA Substance Registry System: 2,4-pyrimidinediamine, 6-chloro-N~4~,N~4~-dimethyl-(1007-11-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1007-11-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4-pyrimidinediamine, 6-chloro-N^4^,N^4^-dimethylis used as an intermediate in the synthesis of various antiviral and antibacterial medications. Its unique chemical structure allows it to be a key component in the development of new drugs that target specific pathogens.
Used as a Research Reagent:
In the field of scientific research, 2,4-pyrimidinediamine, 6-chloro-N^4^,N^4^-dimethylserves as a valuable reagent for studying the properties and reactions of pyrimidine-based compounds. It aids researchers in understanding the mechanisms of action and potential applications of related compounds.
Used in Organic Synthesis:
2,4-pyrimidinediamine, 6-chloro-N^4^,N^4^-dimethylis also utilized in the synthesis of a wide range of organic compounds, including other pharmaceuticals, agrochemicals, and specialty chemicals. Its versatile structure makes it a useful building block for creating new molecules with specific properties and functions.
Safety Precautions:
Due to its potential hazards, 2,4-pyrimidinediamine, 6-chloro-N^4^,N^4^-dimethylshould be handled and stored with care. Proper safety measures, such as wearing protective gear and following established protocols, should be taken to minimize risks associated with its use.

InChI:InChI=1/C6H9ClN4/c1-11(2)5-3-4(7)9-6(8)10-5/h3H,1-2H3,(H2,8,9,10)

Upstream product

• 56-05-3 2-Amino-4,6-dichloropyrimidine 
• 124-40-3 dimethyl amine 
• 506-59-2 N,N-dimethylammonium chloride 

Downstream Products

• 1271022-21-9 C₁₃H₁₂FN₅ 

Relevant articles and documents

Barriers to Rotation of the Dimethylamino Group in Some 2-Amino-4-(N,N-dimethylamino)pyrimidines

The free energy of activation for rotation about the exocyclic C-N bond of the dimethylamino group of some 6-substituted 2-amino-4-(N,N-dimethylamino)pyrimidines has been determined using 1H NMR line shape analysis.The results are discussed in terms of the relative electron-withdrawing and electron-releasing effects of the substituents.

Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors

Phosphoinositide-dependent protein kinase-1(PDK1) is a master regulator of the AGC family of kinases and an integral component of the PI3K/AKT/mTOR pathway. As this pathway is among the most commonly deregulated across all cancers, a selective inhibitor of PDK1 might have utility as an anticancer agent. Herein we describe our lead optimization of compound 1 toward highly potent and selective PDK1 inhibitors via a structure-based design strategy. The most potent and selective inhibitors demonstrated submicromolar activity as measured by inhibition of phosphorylation of PDK1 substrates as well as antiproliferative activity against a subset of AML cell lines. In addition, reduction of phosphorylation of PDK1 substrates was demonstrated in vivo in mice bearing OCl-AML2 xenografts. These observations demonstrate the utility of these molecules as tools to further delineate the biology of PDK1 and the potential pharmacological uses of a PDK1 inhibitor.

CHEMICAL COMPOUNDS

The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

CHEMICAL COMPOUNDS

The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.